MSH2 and neoplasm: Combined loss of MSH2 and MSH6 is rather infrequent in colorectal, endometrial, and gastric cancer, the tumor types with highest prevalence of MSI.47,48 In these entities, the vast majority of sporadic tumors with MSI are associated with MLH1 inactivation due to promotor hypermethylation.